Markov Model and Cost-Effectiveness Analysis of Bevacizumab in HER2-Negative Metastatic Breast Cancer Article

Refaat, Tamer, Choi, Mehee, Gaber, Germaine et al. (2014). Markov Model and Cost-Effectiveness Analysis of Bevacizumab in HER2-Negative Metastatic Breast Cancer . AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 37(5), 480-485. 10.1097/COC.0b013e31827e4e9a

International Collaboration

cited authors

  • Refaat, Tamer; Choi, Mehee; Gaber, Germaine; Kiel, Krystyna; Mehta, Minesh; Gradishar, William; Small, William

sustainable development goals

authors

publication date

  • October 1, 2014

webpage

published in

keywords

  • ANGIOGENESIS
  • BLOOD-VESSELS
  • CHEMOTHERAPY
  • COMBINATION
  • ENDOTHELIAL GROWTH-FACTOR
  • Life Sciences & Biomedicine
  • OSTEONECROSIS
  • Oncology
  • PHASE-III
  • SURVIVAL
  • Science & Technology
  • THERAPY
  • TRIAL
  • bevacizumab
  • breast cancer
  • cost-effectiveness

Digital Object Identifier (DOI)

publisher

  • LIPPINCOTT WILLIAMS & WILKINS

start page

  • 480

end page

  • 485

volume

  • 37

issue

  • 5